Genentech
Untracked preview. This is not a tracked Signal Bureau entity — the page is generated on request from live coverage search, is not indexed, and carries no editorial curation. Tracked entities live on the Wire.
Coverage of Genentech is holding steady : 5 signals on the latest tracked day, level with its three-week baseline of 5, across 2 domains.
Genentech is steady by its own history. Its normal rhythm is about 5 signals a day across 2 domains. A real move would be a day at 7+ signals — 25% above that baseline, the bar our trend read calls accelerating — or a spread into domains beyond its usual 2. That is the move that would push it up the Wire.
What’s changed
- Genentech doubles down on ADC-resistant cancers with $1B DualityBio pact · Reddit r/biotech · 2026-08-30
- BioNTech-Genentech cancer vax records more deaths than control in scrapped ph. 2 test · Reddit r/biotech · 2026-08-30
- IDEAYA Biosciences (IDYA) Is Up 5.2% After Genentech KRAS G12D Trial Collaboration News - Has The Bull Case Changed? - Sahm · KRAS Mutation Research (Google News) · 2026-08-21
- IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer - PR Newswire · KRAS Mutation Research (Google News) · 2026-08-19
- Genentech doubles down on IDEAYA’s PRMT5 strategy with KRAS G12D combo - AllSci · KRAS Mutation Research (Google News) · 2026-08-19
- List of Determinations Including Written Request · FDA — What's New: Drugs · 2026-09-03
What the reporting says
Across 30 tracked stories from 16 outlets, reporting on Genentech most often describes launches or releases (3), regulatory approvals (2), military action (1).
It shows up alongside Astrazeneca (10), Bristol Myers Squibb (10), KRAS (10).
Two steps out: Abstract (through Astrazeneca, 10 shared stories on the weaker link); Braf (through KRAS, 10 shared stories on the weaker link); Colorectal Cancer (through KRAS, 10 shared stories on the weaker link); Egfr (through KRAS, 10 shared stories on the weaker link).
Tracked since May 16, with coverage on 17 separate days — concentrated in Kras Research and Preprint.